How Gilead’s Liver Disease Drugs Portfolio Performed

Gilead’s liver disease drugs 

As discussed earlier, Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others. Over 50% of revenues comes from antiviral products from the liver disease franchise.

How Gilead’s Liver Disease Drugs Portfolio Performed

Liver disease drugs portfolio

The liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.

Harvoni

Harvoni is Gilead’s best-selling drug. Harvoni is used with or without ribavirin for the treatment of chronic hepatitis C virus of genotype-1, genotype-4, genotype-5, and genotype-6. Harvoni reported a decline in revenues of $9.1 billion for 2016 as compared to $13.9 billion for 2015.

Sovaldi

Sovaldi is a drug used in combination with other antivirals for the treatment of chronic hepatitis C virus of genotype-1 to genotype-4. Sovaldi reported revenues of $4.0 billion in 2016 as compared to $5.3 billion for 2015.

Viread

Viread is used in combination with other antiretrovirals for the treatment of patients with HIV-1 infection. It’s also used for the treatment of patients with Hepatitis B virus infection. However, the drug Viread should not be used in combination with other drugs like Atripla, Complera, Stribild, and Truvada. Viread reported revenues of $1.2 billion for 2016 as compared to $1.8 billion for 2015.

Epclusa

Epclusa is a new drug for the treatment of chronic Hepatitis C infection of Genotype-1 to Genotype-6 with or without cirrhosis. For patients who have advanced cirrhosis, the drug is used in combination with Ribavirin. Epclusa will be a new blockbuster drug for the treatment of patients with Hepatitis C infections. The drug reported revenues of $1.8 billion for 2016.

Some of the approved treatments for HCV include Zepatier from Merck (MRK), Daklinza from Bristol-Myers Squibb (BMY), Technivie and Viekira Pak from AbbVie (ABBV), and Olysio for Johnson & Johnson (JNJ).

To divest the risk, investors can consider ETFs like the SPDR S&P Biotech ETF (XBI), which holds ~2.2% of its total assets in Gilead Sciences.